Dual-Targeting Magnetic PLGA Nanoparticles for Codelivery of Paclitaxel and Curcumin for Brain Tumor Therapy

doi:10.1021/acsami.6b10175

CORC > 上海药物研究所 > 中国科学院上海药物研究所 > 药物制剂研究中心

	Dual-Targeting Magnetic PLGA Nanoparticles for Codelivery of Paclitaxel and Curcumin for Brain Tumor Therapy
	Cui, Yanna 2,3; Zhang, Meng 2; Zeng, Feng 1,2,4; Jin, Hongyue 2; Xu, Qin 1; Huang, Yongzhuo2
刊名	ACS APPLIED MATERIALS & INTERFACES
	2016-11-30
卷号	8 期号:47 页码:32159-32169
关键词	brain targeting delivery magnetic targeting PLGA nanoparticles paclitaxel curcumin T7 peptide
ISSN号	1944-8244
DOI	10.1021/acsami.6b10175
文献子类	Article
英文摘要	Chemotherapy is one of the most important strategies for glioma treatment. However, the "impermeability" of the blood brain barrier (BBB) impedes most chemotherapeutics from entering the brain, thereby rendering very few drugs suitable for glioma therapy, letting alone application of a combination of chemotherapeutics. Thereby, there is a pressing need to overcome the obstacles. A dual-targeting strategy was developed by a combination of magnetic guidance and transferrin receptor-binding peptide T7-mediated active targeting delivery. The T7-modified magnetic PLGA nano particle (NP) system was prepared with co-encapsulation of the hydrophobic magnetic nanoparticles and a combination of drugs (i.e., paclitaxel and curcumin) based on a "one-pot" process. The combined drugs yielded synergistic effects on inhibition of tumor growth via the mechanisms of apoptosis induction and cell cycle arrest, displaying significantly increased efficacy relative to the single use of each drug. Dual-targeting effects yielded a >10-fold increase in cellular uptake studies and a >5-fold enhancement in brain delivery compared to the nontargeting NPs. For the in vivo studies with an orthotopic glioma model, efficient brain accumulation was observed by using fluorescence imaging, synchrotron radiation X-ray imaging, and MM. Furthermore, the antiglioma treatment efficacy of the delivery system was evaluated. With application of a magnetic field, this system exhibited enhanced treatment efficiency and reduced adverse effects. All mice bearing orthotopic glioma survived, compared to a 62.5% survival rate for the combination group receiving free drugs. This dual-targeting, co-delivery strategy provides a potential method for improving brain drug delivery and antiglioma treatment efficacy.
资助项目	973 Program, China[2013CB932503] ; 973 Program, China[2014CB931900] ; NFSC[81373357] ; NFSC[81402885] ; NFSC[81422048] ; NFSC[81673382] ; China's Postdoctoral Science Foundation[133646] ; China's Postdoctoral Science Foundation[2014M551475]
WOS关键词	IRON-OXIDE NANOPARTICLES ; TRANSFERRIN RECEPTOR ; DRUG-DELIVERY ; CANCER-CELLS ; DOXORUBICIN ; BARRIER ; TRANSPORT ; SYSTEMS ; ARREST ; MRI
WOS研究方向	Science & Technology - Other Topics ; Materials Science
语种	英语
出版者	AMER CHEMICAL SOC
WOS记录号	WOS:000389161600009
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/275791]
专题	药物制剂研究中心
通讯作者	Huang, Yongzhuo
作者单位	1.Guangzhou Univ Chinese Med, Inst Trop Med, 12 Jichang Rd, Guangzhou 501405, Guangdong, Peoples R China 2.Chinese Acad Sci, Shanghai Inst Mat Med, 501 Haike Rd, Shanghai 201203, Peoples R China; 3.Chinese Acad Sci, Key Lab Primate Neurobiol, Inst Neurosci, Shanghai Inst Biol Sci, 320 Yueyang Rd, Shanghai 200031, Peoples R China; 4.Fudan Univ, Sch Pharm, Minist Educ, Key Lab Smart Drug Delivery, 826 Zhangheng Rd, Shanghai 201203, Peoples R China;
推荐引用方式 GB/T 7714	Cui, Yanna,Zhang, Meng,Zeng, Feng,et al. Dual-Targeting Magnetic PLGA Nanoparticles for Codelivery of Paclitaxel and Curcumin for Brain Tumor Therapy[J]. ACS APPLIED MATERIALS & INTERFACES,2016,8(47):32159-32169.
APA	Cui, Yanna,Zhang, Meng,Zeng, Feng,Jin, Hongyue,Xu, Qin,&Huang, Yongzhuo.(2016).Dual-Targeting Magnetic PLGA Nanoparticles for Codelivery of Paclitaxel and Curcumin for Brain Tumor Therapy.ACS APPLIED MATERIALS & INTERFACES,8(47),32159-32169.
MLA	Cui, Yanna,et al."Dual-Targeting Magnetic PLGA Nanoparticles for Codelivery of Paclitaxel and Curcumin for Brain Tumor Therapy".ACS APPLIED MATERIALS & INTERFACES 8.47(2016):32159-32169.